Jeena Sikho Lifecare reported a robust start to fiscal year 2027, with revenue from operations rising 29% year-on-year (YoY) to ₹22,440 lakh in the first quarter ended June 30, 2026. The Ayurveda healthcare provider posted a 28% YoY increase in profit after taxes (PAT) to ₹6,569 lakh, supported by higher patient footfalls, expanded service networks, and strong momentum in its products business. The company’s earnings conference call, scheduled for August 10, 2026, will provide further management commentary on these results.

The financial performance reflects improving operating leverage and better utilization of existing infrastructure. Revenue grew 4% quarter-on-quarter (QoQ) from ₹21,555 lakh in Q4FY26. Gross profit increased 27% YoY to ₹19,873 lakh, maintaining a gross margin of 89%. The company submitted its investor presentation pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on August 9, 2026.

Operational Highlights

Jeena Sikho Lifecare operates 62 hospitals and 57 clinics across 23 states, with approximately 2,400 operational beds. Inpatient department (IPD) volumes surged 33% YoY, while day care volumes grew 31% YoY to 19,419 patients per day. Outpatient department (OPD) volumes rose 22% YoY. The Panchakarma revenue segment grew 13% YoY, indicating sustained demand for core Ayurvedic treatments.

Business Vertical Performance

The Ayurveda Healthcare Products business delivered 47% YoY growth during the quarter, driven by a broader product portfolio and increasing acceptance of quality-focused Ayurveda offerings. The INJK Water Device, launched in December 2024, emerged as the largest contributor to the product portfolio in Q1FY27. The Services vertical benefited from higher IPD and day care volumes, reinforcing the company’s cross-selling flywheel where medicine buyers visit clinics and clinic patients consume medicines post-treatment.

What the Numbers Show

While revenue growth accelerated to 29% YoY, EBITDA margins contracted by 415 basis points to 41% from 45% in Q1FY26. This divergence suggests that operating expenses, which rose 38% YoY to ₹10,662 lakh, outpaced revenue growth in absolute terms, potentially due to expansion costs or higher marketing spend associated with new facility openings. However, the significant rise in other income (1,212% YoY to ₹1,402 lakh) bolstered the bottom line, contributing to the 28% PAT growth despite the margin compression. Investors should monitor whether operating leverage improves as the 450 beds in pipeline come online, potentially stabilizing margins in subsequent quarters.

Jeena Sikho Lifecare has formally executed the Room Block & Services Licence Agreement for its integrated wellness centre in Manali, Himachal Pradesh, on August 5, 2026. The deal, valued at ₹7.66 crore plus applicable taxes, was approved by the Board of Directors on August 4, 2026, and signed with Mr. Anil Saklani, owner of Ajna Resorts. This execution confirms the company’s expansion into premium wellness hospitality without capital expenditure on property acquisition.

The agreement grants Jeena Sikho Lifecare operational rights over thirty luxury guest rooms, five consultation/treatment rooms, and five exclusive spa treatment rooms at Ajna Resorts in Village Jagatsukh. Operations are scheduled to commence within 60 days of the Effective Date, subject to Commercial Readiness requirements. The transaction is classified as being in the ordinary course of business and is not a related party transaction.

Key Terms of the Executed Agreement

The licence term is set for eleven months from the Commercial Readiness Date. The fee structure requires two equal advance instalments paid at six-month intervals during each Contract Year. Financing will be sourced through internal accruals.

Strategic Impact on Infrastructure

This capacity addition strengthens Jeena Sikho Lifecare’s integrated healthcare offerings by entering the premium wellness retreat market. The company currently operates over 120 Ayurveda clinics and hospitals. The Manali centre will serve as a dedicated hub for health transformation programmes, leveraging the resort’s existing infrastructure. By utilising a licence model, the company avoids heavy capex while rapidly scaling its service footprint in a high-demand tourist destination.

Regulatory disclosures were made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The details have been uploaded to the company’s website for stakeholder reference.